Avadel pharmaceuticals provides corporate update and reports second quarter 2023 financial results

-- successfully commenced u.s. commercial launch of lumryz™ -- -- received final fda approval for lumryz with orphan drug exclusivity granted through may 1, 2030 --
AVDL Ratings Summary
AVDL Quant Ranking